tetano
Editor, Senior Moderator
Eur J Gastroenterol Hepatol
. 2020 Nov 30.
doi: 10.1097/MEG.0000000000002013. Online ahead of print.
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19
Preethi Ramachandran[SUP] 1 [/SUP], Abhilash Perisetti[SUP] 2 [/SUP], Mahesh Gajendran[SUP] 3 [/SUP], Farla Jean-Louis[SUP] 4 [/SUP], Pardeep Bansal[SUP] 5 [/SUP], Alok Kumar Dwivedi[SUP] 6 [/SUP], Hemant Goyal[SUP] 7 [/SUP]
Affiliations
Abstract
Introduction: Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19.
Methods: We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients.
Results: A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables.
Conclusion: We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.
. 2020 Nov 30.
doi: 10.1097/MEG.0000000000002013. Online ahead of print.
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19
Preethi Ramachandran[SUP] 1 [/SUP], Abhilash Perisetti[SUP] 2 [/SUP], Mahesh Gajendran[SUP] 3 [/SUP], Farla Jean-Louis[SUP] 4 [/SUP], Pardeep Bansal[SUP] 5 [/SUP], Alok Kumar Dwivedi[SUP] 6 [/SUP], Hemant Goyal[SUP] 7 [/SUP]
Affiliations
- PMID: 33252418
- DOI: 10.1097/MEG.0000000000002013
Abstract
Introduction: Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19.
Methods: We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients.
Results: A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables.
Conclusion: We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.